Andere talen Roivant Sciences Ltd.

Aandelen

ROIV

BMG762791017

Farmaceutische producten

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 12-12-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,88 ^USD	-1,90%		-1,66%	+5,79%

04/12	Roivant Sciences Ltd. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 02:10 PM
03/12	Kinevant van Roivant Sciences zegt dat kandidaat-geneesmiddel voor longsarcoïdose niet aan de doelstellingen voldoet	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Roivant Sciences' Kinevant Says Pulmonary Sarcoidosis Drug Candidate Fails to Meet Goals	03/12
Roivant Sciences : Announces Topline Results from Phase 2 RESOLVE Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis Form 8 K	03/12
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis	03/12
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis	03/12
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis	03/12
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis	03/12
Roivant Sciences : Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update Form 8 K	12/11
Roivant Sciences' Fiscal Q2 Net Loss Narrows, Revenue Rises	12/11
Earnings Flash (ROIV) ROIVANT SCIENCES Reports Q2 Revenue $4.5M	12/11
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024.	12/11
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update	12/11
Stocks Down Pre-Bell After Record Highs as Earnings Season Wanes; Asia, Europe Fall	12/11
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update	12/11
Roivant Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	12/11
Organon : FDA Extends Vtama Atopic-Dermatitis Review to March	05/11
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024	29/10
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024	29/10
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA Cream, 1%	29/10
Roivant Sciences : Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% Form 8 K	28/10
Organon Finalizes Acquisition of Dermavant From Roivant	28/10
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%	28/10
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%	28/10
Roivant Sciences Insider Sold Shares Worth $1,165,000, According to a Recent SEC Filing	23/10
Roivant Sciences Insider Sold Shares Worth $5,866,308, According to a Recent SEC Filing	27/09
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA Cream, 1%	19/09

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Roivant Sciences Ltd.

Aandelen

ROIV

BMG762791017

Farmaceutische producten

Andere talen

Filters